|
|
Article: KYTHERA Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101.
- Article from:
- Clinical Trials Week
- Article date:
- October 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. Top-line results from these studies, which examined use of ATX-101 for reduction of unwanted localized fat deposits under the chin (submental fat), were announced in January 2009 (http://www.kytherabiopharma.com/press_releases.html) (see also KYTHERA Biopharmaceuticals, Inc.).
Kevin C. Smith MD, FAAD, FRCPC presented study results in Scientific Session at the American Society for Dermatologic Surgery (ASDS) ...